Prevalence of Primary Aldosteronism Among Patients With Hypertension.

IF 2.4 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Clinical Endocrinology Pub Date : 2025-06-29 DOI:10.1111/cen.15296

Divyansh Goyal, Manasvini Bhatt, Tamoghna Ghosh, Prayas Sethi, Ranveer Singh Jadon, Sarah Alam, Rajesh Khadgawat

{"title":"Prevalence of Primary Aldosteronism Among Patients With Hypertension.","authors":"Divyansh Goyal, Manasvini Bhatt, Tamoghna Ghosh, Prayas Sethi, Ranveer Singh Jadon, Sarah Alam, Rajesh Khadgawat","doi":"10.1111/cen.15296","DOIUrl":null,"url":null,"abstract":"Background: Despite being a leading cause of secondary hypertension and association with a higher incidence of cardiovascular morbidity and mortality the prevalence of primary aldosteronism (PA) is poorly studied.Objective: We assessed the prevalence of PA in participants being treated as essential hypertension (EHTN).Design and participants: In this prospective, cross-sectional study, 492 participants with diagnosis of EHTN were evaluated. The screening for PA was conducted by measuring plasma aldosterone concentration (PAC) and direct renin concentration (DRC), from which the aldosterone-to-renin ratio (ARR) was calculated. Based on Endocrine Society guidelines, screening test was followed by a confirmatory recumbent saline infusion test (SIT). Participants who showed a post-SIT PAC greater than 5 ng/dL were diagnosed with PA.Results: Of 492 EHTN participants, 91 (18.49%) had positive screening test. Out of 91 participants, 59 agreed for SIT and PA was confirmed in 37 participants (8.04%) (Excluding 32 screened positive participants who were non-compliant to SIT). The mean age was 49.98 ± 7.76 years, and median duration of hypertension was 5 (0-24) years. The prevalence of PA increased with grade of hypertension (5.97% in grade 1%-12.03% in grade 3), hypertension daily dose (HDD) (3.57% in those with HDD < 1% to 27.27% in those with HDD ≥ 4). No significant difference in hypokalaemia in PA and EHTN (2.70% and 3.54% respectively, p: 0.7815).Conclusions: Our study shows a high prevalence of PA in subjects treated as a case of EHTN.","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cen.15296","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Despite being a leading cause of secondary hypertension and association with a higher incidence of cardiovascular morbidity and mortality the prevalence of primary aldosteronism (PA) is poorly studied.

Objective: We assessed the prevalence of PA in participants being treated as essential hypertension (EHTN).

Design and participants: In this prospective, cross-sectional study, 492 participants with diagnosis of EHTN were evaluated. The screening for PA was conducted by measuring plasma aldosterone concentration (PAC) and direct renin concentration (DRC), from which the aldosterone-to-renin ratio (ARR) was calculated. Based on Endocrine Society guidelines, screening test was followed by a confirmatory recumbent saline infusion test (SIT). Participants who showed a post-SIT PAC greater than 5 ng/dL were diagnosed with PA.

Results: Of 492 EHTN participants, 91 (18.49%) had positive screening test. Out of 91 participants, 59 agreed for SIT and PA was confirmed in 37 participants (8.04%) (Excluding 32 screened positive participants who were non-compliant to SIT). The mean age was 49.98 ± 7.76 years, and median duration of hypertension was 5 (0-24) years. The prevalence of PA increased with grade of hypertension (5.97% in grade 1%-12.03% in grade 3), hypertension daily dose (HDD) (3.57% in those with HDD < 1% to 27.27% in those with HDD ≥ 4). No significant difference in hypokalaemia in PA and EHTN (2.70% and 3.54% respectively, p: 0.7815).

Conclusions: Our study shows a high prevalence of PA in subjects treated as a case of EHTN.

查看原文本刊更多论文

高血压患者原发性醛固酮增多症的患病率。

背景：尽管原发性醛固酮增多症（PA）是继发性高血压的主要原因，并与较高的心血管发病率和死亡率相关，但对其患病率的研究却很少。目的：我们评估作为原发性高血压（EHTN）治疗的参与者中PA的患病率。设计和参与者：在这项前瞻性横断面研究中，对492名诊断为EHTN的参与者进行了评估。通过测定血浆醛固酮浓度（PAC）和直接肾素浓度（DRC）进行PA筛查，计算醛固酮与肾素比值（ARR）。根据内分泌学会指南，筛查试验后进行确认性卧位生理盐水输注试验（SIT）。sit后PAC高于5 ng/dL的参与者被诊断为PA。结果：在492例EHTN参与者中，91例（18.49%）筛查阳性。在91名参与者中，59名参与者同意SIT， 37名参与者（8.04%）确认了PA（不包括32名不符合SIT的筛查阳性参与者）。平均年龄49.98±7.76岁，中位高血压病程5（0 ~ 24）年。PA的患病率随着高血压的等级（1级为5.97%，3级为12.03%）和高血压日剂量（HDD）（HDD者为3.57%）而增加。结论：我们的研究显示，作为EHTN病例的受试者中PA的患病率很高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Endocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

3.10%

发文量

192

审稿时长

1 months

期刊介绍： Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.